Cibus (CBUS) vs Foghorn Therapeutics (FHTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cibus (CBUS) has outperformed Foghorn Therapeutics (FHTX) over the past year, gaining 13.3% versus a loss of 52.7%. Over five years, FHTX leads with a -83.1% price change compared with -98.9% for CBUS. Cibus is the larger company by market cap ($121.9 million vs $119.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBUS | FHTX |
|---|---|---|
| Share price | $1.60 | $2.02 |
| Market cap | $121.90M | $119.66M |
| 1-day change | -1.55% | -3.59% |
| YTD return | -6.90% | -61.30% |
| 1-year return | +13.29% | -52.71% |
| 5-year return | -98.90% | -83.12% |
| EPS (TTM) | $-1.62 | $-0.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.19 | $7.61 |
| 52-week low | $1.09 | $1.79 |
| Distance from 52-week high | -61.94% | -73.52% |
| Analyst consensus | none | buy |
| Avg. price target upside | +798.43% | +197.77% |
| Average volume | 206.34K | 616.68K |
| Shares outstanding | 76.43M | 59.39M |
| Employees | 118 | 106 |
| Sector | Industrials | Health Care |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CBUS has outperformed FHTX by 66.0 percentage points over the past year.
- The two companies sit in different sectors: Cibus in Industrials and Foghorn Therapeutics in Health Care.
About Cibus
CBUS stock →Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits.
Industrials · Agricultural Chemicals · 118 employees
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
CBUS vs FHTX FAQ
Which is bigger, Cibus or Foghorn Therapeutics?
Cibus (CBUS) is larger, with a market capitalization of $121.90M compared with $119.66M for Foghorn Therapeutics (FHTX).
Which stock has performed better over the past year, CBUS or FHTX?
CBUS returned +13.29% over the past 12 months, compared with -52.71% for FHTX (price return, excluding dividends). Past performance does not predict future results.
Are Cibus and Foghorn Therapeutics in the same industry?
No. Cibus is in the Industrials sector, while Foghorn Therapeutics is in Health Care.